Membranoproliferative glomerulonephritis type II (dense deposit disease)

An update

Gerald B. Appel, H. Terence Cook, Gregory Hageman, J. Charles Jennette, Michael Kashgarian, Michael Kirschfink, John D. Lambris, Lynne Lanning, Hans U. Lutz, Seppo Meri, Noel R. Rose, David J. Salant, Sanjeev Sethi, Richard J H Smith, William Smoyer, Hope F. Tully, Sean P. Tully, Patrick Walker, Michael Welsh, Reinhard Würzner & 1 others Peter F. Zipfel

Research output: Contribution to journalArticle

Abstract

Membranoproliferative glomerulonephritis type II (MPGN II) is a rare disease characterized by the deposition of abnormal electron-dense material within the glomerular basement membrane of the kidney and often within Bruch's membrane in the eye. The diagnosis is made in most patients between the ages of 5 and 15 yr, and within 10 yr, approximately half progress to end-stage renal disease, occasionally with the late comorbidity of visual impairment. The pathophysiologic basis of MPGN II is associated with the uncontrolled systemic activation of the alternative pathway (AP) of the complement cascade. In most patients, loss of complement regulation is caused by C3 nephritic factor, an autoantibody directed against the C3 convertase of the AP, but in some patients, mutations in the factor H gene have been identified. For the latter patients, plasma replacement therapy prevents renal failure, but for the majority of patients, there is no proven effective treatment. The disease recurs in virtually all renal allografts, and a high percentage of these ultimately fail. The development of molecular diagnostic tools and new therapies directed at controlling the AP of the complement cascade either locally in the kidney or at the systemic level may lead to effective treatments for MPGN II.

Original languageEnglish (US)
Pages (from-to)1392-1403
Number of pages12
JournalJournal of the American Society of Nephrology
Volume16
Issue number5
DOIs
StatePublished - 2005

Fingerprint

Membranoproliferative Glomerulonephritis
Alternative Complement Pathway
Kidney
Complement C3 Nephritic Factor
Alternative Pathway Complement C3 Convertase
Bruch Membrane
Complement Factor H
Glomerular Basement Membrane
Molecular Pathology
Vision Disorders
Therapeutics
Rare Diseases
Autoantibodies
Chronic Kidney Failure
Renal Insufficiency
Allografts
Comorbidity
Electrons
Mutation
Genes

ASJC Scopus subject areas

  • Nephrology

Cite this

Appel, G. B., Cook, H. T., Hageman, G., Jennette, J. C., Kashgarian, M., Kirschfink, M., ... Zipfel, P. F. (2005). Membranoproliferative glomerulonephritis type II (dense deposit disease): An update. Journal of the American Society of Nephrology, 16(5), 1392-1403. https://doi.org/10.1681/ASN.2005010078

Membranoproliferative glomerulonephritis type II (dense deposit disease) : An update. / Appel, Gerald B.; Cook, H. Terence; Hageman, Gregory; Jennette, J. Charles; Kashgarian, Michael; Kirschfink, Michael; Lambris, John D.; Lanning, Lynne; Lutz, Hans U.; Meri, Seppo; Rose, Noel R.; Salant, David J.; Sethi, Sanjeev; Smith, Richard J H; Smoyer, William; Tully, Hope F.; Tully, Sean P.; Walker, Patrick; Welsh, Michael; Würzner, Reinhard; Zipfel, Peter F.

In: Journal of the American Society of Nephrology, Vol. 16, No. 5, 2005, p. 1392-1403.

Research output: Contribution to journalArticle

Appel, GB, Cook, HT, Hageman, G, Jennette, JC, Kashgarian, M, Kirschfink, M, Lambris, JD, Lanning, L, Lutz, HU, Meri, S, Rose, NR, Salant, DJ, Sethi, S, Smith, RJH, Smoyer, W, Tully, HF, Tully, SP, Walker, P, Welsh, M, Würzner, R & Zipfel, PF 2005, 'Membranoproliferative glomerulonephritis type II (dense deposit disease): An update', Journal of the American Society of Nephrology, vol. 16, no. 5, pp. 1392-1403. https://doi.org/10.1681/ASN.2005010078
Appel, Gerald B. ; Cook, H. Terence ; Hageman, Gregory ; Jennette, J. Charles ; Kashgarian, Michael ; Kirschfink, Michael ; Lambris, John D. ; Lanning, Lynne ; Lutz, Hans U. ; Meri, Seppo ; Rose, Noel R. ; Salant, David J. ; Sethi, Sanjeev ; Smith, Richard J H ; Smoyer, William ; Tully, Hope F. ; Tully, Sean P. ; Walker, Patrick ; Welsh, Michael ; Würzner, Reinhard ; Zipfel, Peter F. / Membranoproliferative glomerulonephritis type II (dense deposit disease) : An update. In: Journal of the American Society of Nephrology. 2005 ; Vol. 16, No. 5. pp. 1392-1403.
@article{91072475b8de49159c5171dbcee1adfb,
title = "Membranoproliferative glomerulonephritis type II (dense deposit disease): An update",
abstract = "Membranoproliferative glomerulonephritis type II (MPGN II) is a rare disease characterized by the deposition of abnormal electron-dense material within the glomerular basement membrane of the kidney and often within Bruch's membrane in the eye. The diagnosis is made in most patients between the ages of 5 and 15 yr, and within 10 yr, approximately half progress to end-stage renal disease, occasionally with the late comorbidity of visual impairment. The pathophysiologic basis of MPGN II is associated with the uncontrolled systemic activation of the alternative pathway (AP) of the complement cascade. In most patients, loss of complement regulation is caused by C3 nephritic factor, an autoantibody directed against the C3 convertase of the AP, but in some patients, mutations in the factor H gene have been identified. For the latter patients, plasma replacement therapy prevents renal failure, but for the majority of patients, there is no proven effective treatment. The disease recurs in virtually all renal allografts, and a high percentage of these ultimately fail. The development of molecular diagnostic tools and new therapies directed at controlling the AP of the complement cascade either locally in the kidney or at the systemic level may lead to effective treatments for MPGN II.",
author = "Appel, {Gerald B.} and Cook, {H. Terence} and Gregory Hageman and Jennette, {J. Charles} and Michael Kashgarian and Michael Kirschfink and Lambris, {John D.} and Lynne Lanning and Lutz, {Hans U.} and Seppo Meri and Rose, {Noel R.} and Salant, {David J.} and Sanjeev Sethi and Smith, {Richard J H} and William Smoyer and Tully, {Hope F.} and Tully, {Sean P.} and Patrick Walker and Michael Welsh and Reinhard W{\"u}rzner and Zipfel, {Peter F.}",
year = "2005",
doi = "10.1681/ASN.2005010078",
language = "English (US)",
volume = "16",
pages = "1392--1403",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "5",

}

TY - JOUR

T1 - Membranoproliferative glomerulonephritis type II (dense deposit disease)

T2 - An update

AU - Appel, Gerald B.

AU - Cook, H. Terence

AU - Hageman, Gregory

AU - Jennette, J. Charles

AU - Kashgarian, Michael

AU - Kirschfink, Michael

AU - Lambris, John D.

AU - Lanning, Lynne

AU - Lutz, Hans U.

AU - Meri, Seppo

AU - Rose, Noel R.

AU - Salant, David J.

AU - Sethi, Sanjeev

AU - Smith, Richard J H

AU - Smoyer, William

AU - Tully, Hope F.

AU - Tully, Sean P.

AU - Walker, Patrick

AU - Welsh, Michael

AU - Würzner, Reinhard

AU - Zipfel, Peter F.

PY - 2005

Y1 - 2005

N2 - Membranoproliferative glomerulonephritis type II (MPGN II) is a rare disease characterized by the deposition of abnormal electron-dense material within the glomerular basement membrane of the kidney and often within Bruch's membrane in the eye. The diagnosis is made in most patients between the ages of 5 and 15 yr, and within 10 yr, approximately half progress to end-stage renal disease, occasionally with the late comorbidity of visual impairment. The pathophysiologic basis of MPGN II is associated with the uncontrolled systemic activation of the alternative pathway (AP) of the complement cascade. In most patients, loss of complement regulation is caused by C3 nephritic factor, an autoantibody directed against the C3 convertase of the AP, but in some patients, mutations in the factor H gene have been identified. For the latter patients, plasma replacement therapy prevents renal failure, but for the majority of patients, there is no proven effective treatment. The disease recurs in virtually all renal allografts, and a high percentage of these ultimately fail. The development of molecular diagnostic tools and new therapies directed at controlling the AP of the complement cascade either locally in the kidney or at the systemic level may lead to effective treatments for MPGN II.

AB - Membranoproliferative glomerulonephritis type II (MPGN II) is a rare disease characterized by the deposition of abnormal electron-dense material within the glomerular basement membrane of the kidney and often within Bruch's membrane in the eye. The diagnosis is made in most patients between the ages of 5 and 15 yr, and within 10 yr, approximately half progress to end-stage renal disease, occasionally with the late comorbidity of visual impairment. The pathophysiologic basis of MPGN II is associated with the uncontrolled systemic activation of the alternative pathway (AP) of the complement cascade. In most patients, loss of complement regulation is caused by C3 nephritic factor, an autoantibody directed against the C3 convertase of the AP, but in some patients, mutations in the factor H gene have been identified. For the latter patients, plasma replacement therapy prevents renal failure, but for the majority of patients, there is no proven effective treatment. The disease recurs in virtually all renal allografts, and a high percentage of these ultimately fail. The development of molecular diagnostic tools and new therapies directed at controlling the AP of the complement cascade either locally in the kidney or at the systemic level may lead to effective treatments for MPGN II.

UR - http://www.scopus.com/inward/record.url?scp=23944468114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944468114&partnerID=8YFLogxK

U2 - 10.1681/ASN.2005010078

DO - 10.1681/ASN.2005010078

M3 - Article

VL - 16

SP - 1392

EP - 1403

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 5

ER -